BioCryst Pharmaceuticals, Inc.

Q2 2026 13F Holders

Symbol
BCRX
CUSIP
09058V103
Type
Equity
Class
COM
Num filings
338
Total reported value, excl. options
$2.89 B
Manager Report Date Value ($000) Shares Option Type